Current Concept on the Pathogenesis of Inflammatory Bowel Disease-crosstalk Between Genetic and Microbial Factors: Pathogenic Bacteria and Altered Bacterial Sensing or Changes in Mucosal Integrity Take "toll" ?

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2006 Apr 13

PMID 16609988

Citations 43

Authors

Peter Laszlo Lakatos

Simon Fischer

Laszlo Lakatos

Istvan Gal

Janos Papp

Affiliations

Soon will be listed here.

Abstract

The pathogenesis of inflammatory bowel disease (IBD) is only partially understood. Various environmental and host (e.g. genetic-, epithelial-, immune and non-immune) factors are involved. It is a multifactorial polygenic disease with probable genetic heterogeneity. Some genes are associated with IBD itself, while others increase the risk of ulcerative colitis (UC) or Crohn's disease (CD) or are associated with disease location and/or behaviour. This review addresses recent advances in the genetics of IBD. The article discusses the current information on the crosstalk between microbial and genetic factors (e.g. NOD2/CARD15, SLC22A46A5 and DLG5). The genetic data acquired in recent years help in understanding the pathogenesis of IBD and can identify a number of potential targets for therapeutic intervention. In the future, genetics may help more accurately diagnose and predict disease course in IBD.

Citing Articles

Experimental allergic airway inflammation impacts gut homeostasis in mice.

Nascimento C, Casaro M, Perez E, Ribeiro W, Mayer M, Ishikawa K Heliyon. 2023; 9(6):e16429.

PMID: 37484240 PMC: 10360590. DOI: 10.1016/j.heliyon.2023.e16429.

Complementary and alternative medicine use and its association with medication adherence in inflammatory bowel disease and other gastrointestinal diseases.

Almakadma A, De Vol A, Alabdaljabar M, Aldosari S, Muhsen I, Alfreihi O Saudi J Gastroenterol. 2023; 29(4):233-239.

PMID: 37282444 PMC: 10445501. DOI: 10.4103/sjg.sjg_468_22.

PROBIOTIC APPROACHES FOR TARGETING INFLAMMATORY BOWEL DISEASE: AN UPDATE ON ADVANCES AND OPPORTUNITIES IN MANAGING THE DISEASE.

Kumar M, Hemalatha R, Nagpal R, Singh B, Parasannanavar D, Verma V Int J Probiotics Prebiotics. 2019; 11(3-4):99-116.

PMID: 31452650 PMC: 6709984.

Lack of Association between Interleukin 23R (IL-23R) rs10889677 Polymorphism and Inflammatory Bowel Disease Susceptibility In an Iranian Population.

Karimkhani S, Chaleshi V, Balaii H, Tarban P, Nourian M, Irani S Rep Biochem Mol Biol. 2018; 7(1):16-22.

PMID: 30324113 PMC: 6175595.

Epidemiology and hospital resources use in the treatment of ulcerative colitis at gastroenterology units in Spain (EPICURE study).

Marin-Jimenez I, Saro C, Diaz V, Barreiro-de Acosta M, Gomez-Garcia M, Gutierrez Casbas A Drugs Context. 2018; 7:212505.

PMID: 29535792 PMC: 5842877. DOI: 10.7573/dic.212505.

References

Rosenstiel P, Fantini M, Brautigam K, Kuhbacher T, Waetzig G, Seegert D . TNF-alpha and IFN-gamma regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology. 2003; 124(4):1001-9. DOI: 10.1053/gast.2003.50157. View

Mayberry J, Rhodes J . Epidemiological aspects of Crohn's disease: a review of the literature. Gut. 1984; 25(8):886-99. PMC: 1432571. DOI: 10.1136/gut.25.8.886. View

Lakatos P, LAKATOS L, Par A, Papp J . [Molecular genetics and gene therapy in diseases of the esophagus, stomach, colon and pancreas]. Orv Hetil. 2002; 142(52):2883-91. View

Chamaillard M, Philpott D, Girardin S, Zouali H, Lesage S, Chareyre F . Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases. Proc Natl Acad Sci U S A. 2003; 100(6):3455-60. PMC: 152314. DOI: 10.1073/pnas.0530276100. View

Fisher N, Yee L, Nightingale P, McEwan R, Gibson J . Measles virus serology in Crohn's disease. Gut. 1997; 41(1):66-9. PMC: 1027230. DOI: 10.1136/gut.41.1.66. View

Malizia G, Calabrese A, Cottone M, Raimondo M, Trejdosiewicz L, Smart C . Expression of leukocyte adhesion molecules by mucosal mononuclear phagocytes in inflammatory bowel disease. Gastroenterology. 1991; 100(1):150-9. DOI: 10.1016/0016-5085(91)90595-c. View

Seksik P, Rigottier-Gois L, Gramet G, Sutren M, Pochart P, Marteau P . Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut. 2003; 52(2):237-42. PMC: 1774977. DOI: 10.1136/gut.52.2.237. View

Mylonaki M, Langmead L, Pantes A, Johnson F, Rampton D . Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol. 2004; 16(8):775-8. DOI: 10.1097/01.meg.0000131040.38607.09. View

Ruemmele F, Beaulieu J, Dionne S, Levy E, Seidman E, Cerf-Bensussan N . Lipopolysaccharide modulation of normal enterocyte turnover by toll-like receptors is mediated by endogenously produced tumour necrosis factor alpha. Gut. 2002; 51(6):842-8. PMC: 1773452. DOI: 10.1136/gut.51.6.842. View

10.

Crawford N, Eichenberger M, Colliver D, Lewis R, Cobbs G, Petras R . Evaluation of SLC11A1 as an inflammatory bowel disease candidate gene. BMC Med Genet. 2005; 6:10. PMC: 555593. DOI: 10.1186/1471-2350-6-10. View

11.

Stoll M, Corneliussen B, Costello C, Waetzig G, Mellgard B, Andreas Koch W . Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet. 2004; 36(5):476-80. DOI: 10.1038/ng1345. View

12.

Schulte C, Dignass A, Goebell H, Roher H, Schulte K . Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology. 2000; 119(4):909-20. DOI: 10.1053/gast.2000.18158. View

13.

Neurath M, Fuss I, Schurmann G, Pettersson S, Arnold K, Strober W . Cytokine gene transcription by NF-kappa B family members in patients with inflammatory bowel disease. Ann N Y Acad Sci. 1999; 859:149-59. DOI: 10.1111/j.1749-6632.1998.tb11119.x. View

14.

Peters K, OCallaghan N, Cavanaugh J . Lack of association of the CD14 promoter polymorphism--159C/T with Caucasian inflammatory bowel disease. Scand J Gastroenterol. 2005; 40(2):194-7. DOI: 10.1080/00365520510011506. View

15.

Targan S, Landers C, Yang H, Lodes M, Cong Y, Papadakis K . Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology. 2005; 128(7):2020-8. DOI: 10.1053/j.gastro.2005.03.046. View

16.

Brant S, Panhuysen C, Nicolae D, Reddy D, Bonen D, Karaliukas R . MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet. 2003; 73(6):1282-92. PMC: 1180394. DOI: 10.1086/379927. View

17.

Aldhous M, Nimmo E, Satsangi J . NOD2/CARD15 and the Paneth cell: another piece in the genetic jigsaw of inflammatory bowel disease. Gut. 2003; 52(11):1533-5. PMC: 1773871. DOI: 10.1136/gut.52.11.1533. View

18.

Torok H, Glas J, Tonenchi L, Bruennler G, Folwaczny M, Folwaczny C . Crohn's disease is associated with a toll-like receptor-9 polymorphism. Gastroenterology. 2004; 127(1):365-6. DOI: 10.1053/j.gastro.2004.05.051. View

19.

Wall S, Kunze Z, Saboor S, Soufleri I, Seechurn P, Chiodini R . Identification of spheroplast-like agents isolated from tissues of patients with Crohn's disease and control tissues by polymerase chain reaction. J Clin Microbiol. 1993; 31(5):1241-5. PMC: 262911. DOI: 10.1128/jcm.31.5.1241-1245.1993. View

20.

Wehkamp J, Harder J, Weichenthal M, Schwab M, Schaffeler E, Schlee M . NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut. 2004; 53(11):1658-64. PMC: 1774270. DOI: 10.1136/gut.2003.032805. View